UNSPSC 51152050: Baclofen hydrochloride

This classification denotes a muscle relaxant with the molecular formula C10H12CLNO2.CLH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 64OSE3996V. Most nations, for tariff and trade purposes, schedule baclofen hydrochloride under HS 29224995. As of Q4 2014, BACLOFEN HYDROCHLORIDE remains US FDA's Preferred Term for this commodity. Baclofen hydrochloride bears US NLM identifiers UMLS ID C2983921 and NCI Concept Code C90887. SMILES: C1CC(CCC1C(CC(=O)O)CN)CL.CL.

UNSPSC 51152050 Baclofen hydrochloride is a Commodity code that nominally covers a specific muscle relaxant pharmaceutical, but recent state and local procurement activity tagged to this code shows a significant mismatch. The posted opportunities involve naloxone procurement and direct-to-manufacturer prescription programs — neither of which relates to baclofen. State and local governments appear to use this code inconsistently or apply it to broader pharmaceutical acquisition frameworks that do not align with the specific active pharmaceutical ingredient the code nominally identifies. The code shows little relevant recent activity directly supporting baclofen hydrochloride purchasing.

Seminole County, Florida issued IFB 60459723LAS in June 2026 for 1,900 units of naloxone and 800 safe drug deactivation systems annually through competitive bidding with quarterly deliveries to the county community health building, and the Texas Health and Human Services Commission posted RFI HHS0017013 in April 2026 to gather vendor capabilities for a direct-to-manufacturer prescription program outside traditional pharmacy benefit manager and wholesaler channels. The geographic activity appears limited to Florida and Texas based on recent postings. Neither opportunity directly reflects baclofen purchasing, and the code's utility for business development in state and local pharmaceutical procurement depends on clarifying whether the tag reflects a data classification error or a state-local practice of bundling pharmaceutical categories under a single UNSPSC line.